fda tirzepatide weight loss Approves Tirzepatide, A Potential Blockbuster Drug for Type 2 Diabetes GLP-1 Medications for Weight Loss:

Reduces IGFBP affinity by approximately 100-fold while maintaining full IGF-1 receptor binding capacity

Langmuir 19:55675569

10.1038/nrneurol.2013.203 10 AleksicD.PoleksicJ.AgatonovicG.DjulejicV.VulovicM.AksicM.et al

Combined sales of #Mounjaro + #Zepbound reached $36.5B in 2025 That figure surpassed Mercks #Keytruda, which generated $31.7B With stakes this high, control over manufacturing, safety oversight, and supply chains is becoming a central battleground in the obesity drug market

Timing your meals and medication appropriately can help minimise gastrointestinal side effects and subsequent dehydration risk

The practical consequences: biosimilar uptake in the first year after reference product LOE has historically been 30%70% of volume rather than the 80%90% share shift seen in competitive small-molecule markets